摘要
目的探讨不同的他汀药物短期、大剂量应用对行冠脉介入治疗的患者术后肾功能的影响及其可能的机制。方法选择2015年3月~2016年3月在徐州市中心医院心内科行冠脉介入治疗的患者180例,按随机数字表法将其随机分为瑞舒伐他汀组、阿托伐他汀组和对照组,每组各60例。术前3 d至术后3 d,瑞舒伐他汀组给予瑞舒伐他汀20 mg/d治疗,阿托伐他汀组给予阿托伐他汀80 mg/d治疗,对照组不给予任何他汀药物治疗。三组患者术前、术后48~72 h采血测定血肌酐和超敏C反应蛋白水平,比较三组对比剂肾病的发生率、术前及术后超敏C反应蛋白水平。结果瑞舒伐他汀组和阿托伐他汀组对比剂肾病发病率明显低于对照组,差异有统计学意义(P<0.05),瑞舒伐他汀组与阿托伐他汀组比较,差异无统计学意义(P>0.05)。瑞舒伐他汀组和阿托伐他汀组术后超敏C反应蛋白升高程度均低于对照组,差异有统计学意义(P<0.05),但瑞舒伐他汀组和阿托伐他汀组比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀和阿托伐他汀短期、大剂量应用可以降低对比剂肾病的发病率,并且可以降低术后超敏C反应蛋白的升高。
Objective To investigate the effect of short-term and high dose of different statins on the renal function of patients underwent percutaneous coronary intervention and its possible mechanism. Methods One hundred and eighty patients underwent percutaneous coronary intervention in Department of Cardiology, Xuzhou Central Hospital from March 2015 to March 2016 were selected, and they were randomly divided into Rosuvastatin group, Atorvastatin group, and control group according to the random number table, with 60 cases in each group. From 3 d before operation to 3 d after operation, Rosuvastatin group was treated with 20 mg/d, Atorvastatin group was treated with Atorvastatin 80mg/d, the control group was not given any statins. Before operation and 48-72 h after operation, the blood of three groups was draw to detect the levels of serum creatinine and hypersensitive C-reactive protein. The incidence of contrast-induced nephropatby and the levels of hypersensitive C-reactive protein among the three groups were compared. Results The incidence of contrast-induced nephropathy in Rosuvastatin group and Atorvastatin group was lower than that of control group, there were statistically significant differences （P 〈 0.05）, while there was no statistically significant difference between Rosuvastatin group and Atorvastatin group （P 〉 0.05）. The increased degree of postoperative hypersensitive C- reactive protein in Rosuvastatin group and Atorvastatin group was lower than that of control group, there were statistically significant differences （P 〈 0.05）, while there was no statistically significant difference between Rosuvastatin group and Atorvastatin group （P 〉 0.05）. Conclusion Short-term and high dose of Rosuvastatin and Atorvastatin can decrease the incidence of contrast-induced nephropathy and the increase of postoperative hypersensitive C-reactive protein.
作者
娄明
宫海滨
刘奕
王璐璐
曹秋玫
LOU Ming GONG Haibin LIU Yi WANG Lulu CAO Qiumei(Department of Cardiology, Xuzhou Central Hospital, Jiangsu Province, Xuzhou 221009, China Xuzhou Institue of Cardiovascular Disease, Jiangsu Province, Xuzhou 221009, China)
出处
《中国医药导报》
CAS
2017年第29期57-60,共4页
China Medical Herald
基金
江苏省徐州市科学技术局社会发展基金项目(XZZD1379)
关键词
经皮冠状动脉介入治疗
他汀
对比剂肾病
血肌酐
超敏C反应蛋白
Percutaneous coronary intervention
Statin
Contrast-induced nephropathy
Serum ereati-nine
Hypersensitive C-reactive protein
